person · Reporting owner

Morrison Scott W

Disclosed activity across 7 companies

Tapewire entity: 34850
SEC CIK: 0001662426

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Corvus Pharmaceuticals, Inc.CRVS · Entity 4839	Director	June 12, 2025	June 16, 2025
IDEAYA Biosciences, Inc.IDYA · Entity 4069	Director	June 16, 2026	June 18, 2026
Tarsus Pharmaceuticals, Inc.TARS · Entity 1836	Director	June 25, 2026	June 29, 2026
Vera Therapeutics, Inc.VERA · Entity 4358	Director	May 21, 2026	May 26, 2026
Zai Lab LtdZLAB · Entity 4271	Director	June 17, 2026	June 22, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Corvus Pharmaceuticals, Inc.

Report date June 12, 2025 · Filed June 16, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.24 · Expires 2035-06-12	Direct	15,000	Reported balance After 2025-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-06-12 · Grant · Acquired 15,000 · Balance 15,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

IDEAYA Biosciences, Inc.

Report date June 16, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.57 · Expires 2036-06-16	Direct	20,000	Reported balance After 2026-06-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-16 · Grant · Acquired 20,000 · Balance 20,000 F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.

Tarsus Pharmaceuticals, Inc.

Report date June 25, 2026 · Filed June 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.34 · Expires 2036-06-24	Direct	3,837	Reported balance After 2026-06-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-25 · Grant · Acquired 3,837 · Balance 3,837 F1: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	2,417	Reported balance After 2026-06-25 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-25 · Grant · Acquired 2,417 · Balance 2,417 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Filing footnotes · ownership attribution and instrument terms

F1: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

F3: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Vera Therapeutics, Inc.

Report date May 21, 2026 · Filed May 26, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.35 · Expires 2036-05-20	Direct	17,084	Reported balance After 2026-05-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-21 · Grant · Acquired 17,084 · Balance 17,084 F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.

Zai Lab Ltd

Report date June 17, 2026 · Filed June 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
American Depositary SharesSEC Table I · non-derivative	Direct	56,904	Reported balance After 2026-06-17 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-17 · Grant · Acquired 22,371 · Balance 56,904 F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. F2: Represents restricted shares that vest in full on June 17, 2027, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.

F2: Represents restricted shares that vest in full on June 17, 2027, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Audentes Therapeutics, Inc.

Report date January 15, 2020 · Filed January 15, 2020

Section 16 reporting ended · disclosed 2020-01-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.50 · Expires 2025-12-26	Direct	Reported balance After 2020-01-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-01-15 · Disposition to issuer · Disposed 33,635 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.03 · Expires 2026-08-24	Direct	Reported balance After 2020-01-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-01-15 · Disposition to issuer · Disposed 9,000 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.15 · Expires 2027-10-08	Direct	Reported balance After 2020-01-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-01-15 · Disposition to issuer · Disposed 9,000 · Balance 0 F3: Reflects the correct exercise price of this option. The exercise price of this option was previously reported as $26.01. F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.65 · Expires 2028-06-08	Direct	Reported balance After 2020-01-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-01-15 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.74 · Expires 2029-02-06	Direct	Reported balance After 2020-01-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-01-15 · Disposition to issuer · Disposed 16,200 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price.

F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.

F3: Reflects the correct exercise price of this option. The exercise price of this option was previously reported as $26.01.

Global Blood Therapeutics, Inc.

Report date October 05, 2022 · Filed October 06, 2022

Section 16 reporting ended · disclosed 2022-10-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-10-05 transaction · row 1 1 source row Row 1 · 2022-10-05 · Disposition to issuer · Disposed 6,637 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-10-05 · Disposition to issuer · Disposed 3,600 · Balance 0 F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.21	Direct	Reported balance After 2022-10-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-10-05 · Disposition to issuer · Disposed 30,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.85	Direct	Reported balance After 2022-10-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-10-05 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.45	Direct	Reported balance After 2022-10-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-10-05 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.25	Direct	Reported balance After 2022-10-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-10-05 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.30	Direct	Reported balance After 2022-10-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-10-05 · Disposition to issuer · Disposed 7,500 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.75	Direct	Reported balance After 2022-10-05 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-10-05 · Disposition to issuer · Disposed 5,247 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.09	Direct	Reported balance After 2022-10-05 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.30	Direct	Reported balance After 2022-10-05 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.

F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 11, 2022 Filed Aug 15, 2022 22:39 UTC	Corvus Pharmaceuticals, Inc. CRVS · Entity 4839	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $0.97	$0.00	Disclosure SEC source: 0001567619-22-016294 · doc1.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-08-11 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from August 11, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
June 15, 2022 Filed Jun 18, 2022 01:31 UTC	Corvus Pharmaceuticals, Inc. CRVS · Entity 4839	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $0.99	$0.00	Disclosure SEC source: 0001567619-22-013140 · doc1.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document
June 14, 2022 Filed Jun 16, 2022 18:00 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantRestricted Stock Units · Derivative	3,600	$0.00	$0.00	Disclosure SEC source: 0000899243-22-022888 · doc4.xml · derivative · entry 4 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Underlying: Common Stock · 3,600 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 14, 2022 Filed Jun 16, 2022 18:00 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (Right to Buy) · Derivative	5,600	$0.00 Strike: $22.30	$0.00	Disclosure SEC source: 0000899243-22-022888 · doc4.xml · derivative · entry 3 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,600 Underlying: Common Stock · 5,600 shares Expires 2032-06-13 F3 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 14, 2022 for 11 months and the remaining 1/12th on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 14, 2022 Filed Jun 16, 2022 18:00 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	3,600	$0.00	$0.00	Disclosure SEC source: 0000899243-22-022888 · doc4.xml · derivative · entry 2 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vested in a single installment on June 14, 2022. F2 · derivative.expiration_date: The RSUs vested in a single installment on June 14, 2022. Read SEC document
June 14, 2022 Filed Jun 16, 2022 18:00 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	3,600	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-022888 · doc4.xml · nonDerivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,637 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
June 09, 2022 Filed Jun 10, 2022 22:23 UTC	IDEAYA Biosciences, Inc. IDYA · Entity 4069	GrantStock Option (Right to Buy) · Derivative	11,000	$0.00 Strike: $12.29	$0.00	Disclosure SEC source: 0001567619-22-012697 · doc1.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document
May 24, 2022 Filed May 26, 2022 20:09 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	GrantStock Option (right to buy) · Derivative	9,925	$0.00 Strike: $16.14	$0.00	Disclosure SEC source: 0001209191-22-032168 · doc4.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,925 Underlying: Class A Common Stock · 9,925 shares Expires 2032-05-23 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. Read SEC document
October 18, 2021 Filed Oct 18, 2021 12:20 UTC	Zai Lab Ltd ZLAB · Entity 4271	GrantOrdinary Shares	7,345	$0.00	$0.00	Disclosure SEC source: 0000899243-21-040423 · doc4.xml · nonDerivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,345 Read SEC document
September 09, 2021 Filed Sep 10, 2021 20:00 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	4,800	$30.21	$145,002.72	Disclosure SEC source: 0000899243-21-035590 · doc4.xml · nonDerivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,037 F1 · price: Represents the weighted average sale price of the shares sold ranging from $30.1800 to $30.2850 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 09, 2021 Filed Sep 13, 2021 20:51 UTC	Corvus Pharmaceuticals, Inc. CRVS · Entity 4839	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $2.60	$0.00	Disclosure SEC source: 0001567619-21-017008 · doc1.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-09-09 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the first anniversary of the grant date. Read SEC document
June 17, 2021 Filed Jun 21, 2021 16:14 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantRestricted Stock Units · Derivative	3,600	$0.00	$0.00	Disclosure SEC source: 0000899243-21-024967 · doc4.xml · derivative · entry 4 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Underlying: Common Stock · 3,600 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 17, 2021 Filed Jun 21, 2021 16:14 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (Right to Buy) · Derivative	5,600	$0.00 Strike: $37.09	$0.00	Disclosure SEC source: 0000899243-21-024967 · doc4.xml · derivative · entry 3 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,600 Underlying: Common Stock · 5,600 shares Expires 2031-06-16 F3 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 17, 2021 for 11 months and the remaining 1/12th on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 17, 2021 Filed Jun 21, 2021 16:14 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	3,037	$0.00	$0.00	Disclosure SEC source: 0000899243-21-024967 · doc4.xml · derivative · entry 2 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,037 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vested in a single installment on June 17, 2021. F2 · derivative.expiration_date: The RSUs vested in a single installment on June 17, 2021. Read SEC document
June 17, 2021 Filed Jun 21, 2021 16:14 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	3,037	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-024967 · doc4.xml · nonDerivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
June 15, 2021 Filed Jun 16, 2021 20:17 UTC	Corvus Pharmaceuticals, Inc. CRVS · Entity 4839	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $2.74	$0.00	Disclosure SEC source: 0001567619-21-012193 · doc1.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document
June 10, 2021 Filed Jun 16, 2021 21:04 UTC	IDEAYA Biosciences, Inc. IDYA · Entity 4069	GrantStock Option (right to buy) · Derivative	11,000	$0.00 Strike: $21.66	$0.00	Disclosure SEC source: 0001567619-21-012205 · doc1.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document
May 13, 2021 Filed May 18, 2021 00:41 UTC	Vera Therapeutics, Inc. VERA · Entity 4358	GrantStock Option (right to buy) · Derivative	9,925	$0.00 Strike: $11.00	$0.00	Disclosure SEC source: 0001209191-21-033349 · doc4.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,925 Underlying: Class A Common Stock · 9,925 shares Expires 2031-05-12 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 13, 2022 or the 2022 annual meeting of stockholders. Read SEC document
June 17, 2020 Filed Jun 19, 2020 21:32 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantRestricted Stock Units · Derivative	3,037	$0.00	$0.00	Disclosure SEC source: 0000899243-20-017317 · doc4.xml · derivative · entry 4 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,037 Underlying: Common Stock · 3,037 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 17, 2020 Filed Jun 19, 2020 21:32 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (Right to Buy) · Derivative	5,247	$0.00 Strike: $64.75	$0.00	Disclosure SEC source: 0000899243-20-017317 · doc4.xml · derivative · entry 3 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,247 Underlying: Common Stock · 5,247 shares Expires 2030-06-16 F3 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 17, 2020 for 11 months and the remaining 1/12th on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 17, 2020 Filed Jun 19, 2020 21:32 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	4,800	$0.00	$0.00	Disclosure SEC source: 0000899243-20-017317 · doc4.xml · derivative · entry 2 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vested in a single installment on June 17, 2020, the date of the Issuer's annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. F2 · derivative.expiration_date: The RSUs vested in a single installment on June 17, 2020, the date of the Issuer's annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document
June 17, 2020 Filed Jun 19, 2020 21:32 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	4,800	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-017317 · doc4.xml · nonDerivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
June 16, 2020 Filed Jun 18, 2020 20:44 UTC	IDEAYA Biosciences, Inc. IDYA · Entity 4069	GrantStock Option (right to buy) · Derivative	11,000	$0.00 Strike: $12.84	$0.00	Disclosure SEC source: 0001567619-20-012377 · doc1.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2030-06-15 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document
June 09, 2020 Filed Jun 12, 2020 21:14 UTC	Corvus Pharmaceuticals, Inc. CRVS · Entity 4839	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $3.27	$0.00	Disclosure SEC source: 0001567619-20-012101 · doc1.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-09 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document
March 19, 2020 Filed Mar 23, 2020 21:29 UTC	Corvus Pharmaceuticals, Inc. CRVS · Entity 4839	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $2.00	$0.00	Disclosure SEC source: 0001567619-20-006907 · doc1.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-03-19 F1 · derivative.exercise_date: 100% of the shares subject to the option vest and become exercisable on the one-year anniversary of the grant date, subject to continued service as a director through such date. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:33 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	Disposition to issuerStock Option (Right to Buy) · Derivative	16,200	Not disclosed Strike: $24.74	Not disclosed	Disclosure SEC source: 0001209191-20-003432 · doc4.xml · derivative · entry 5 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,200 shares Expires 2029-02-06 F1 · kind: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:33 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	Not disclosed Strike: $38.65	Not disclosed	Disclosure SEC source: 0001209191-20-003432 · doc4.xml · derivative · entry 4 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-06-08 F1 · kind: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:33 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	Disposition to issuerStock Option (Right to Buy) · Derivative	9,000	Not disclosed Strike: $26.15	Not disclosed	Disclosure SEC source: 0001209191-20-003432 · doc4.xml · derivative · entry 3 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2027-10-08 F3 · derivative.exercise_price: Reflects the correct exercise price of this option. The exercise price of this option was previously reported as $26.01. F1 · kind: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:33 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	Disposition to issuerStock Option (Right to Buy) · Derivative	9,000	Not disclosed Strike: $15.03	Not disclosed	Disclosure SEC source: 0001209191-20-003432 · doc4.xml · derivative · entry 2 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2026-08-24 F1 · kind: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:33 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	Disposition to issuerStock Option (Right to Buy) · Derivative	33,635	Not disclosed Strike: $9.50	Not disclosed	Disclosure SEC source: 0001209191-20-003432 · doc4.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,635 shares Expires 2025-12-26 F1 · kind: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
September 24, 2019 Filed Dec 20, 2019 00:09 UTC	IDEAYA Biosciences, Inc. IDYA · Entity 4069	GrantStock Option (right to buy) · Derivative	1,250	$0.00 Strike: $9.15	$0.00	Disclosure SEC source: 0001567619-19-023459 · doc1.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires 2029-09-23 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document
June 20, 2019 Filed Jun 24, 2019 20:06 UTC	Corvus Pharmaceuticals, Inc. CRVS · Entity 4839	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $3.61	$0.00	Disclosure SEC source: 0000899243-19-017919 · doc4.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-20 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document
June 18, 2019 Filed Jun 20, 2019 16:04 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantRestricted Stock Units · Derivative	4,800	$0.00	$0.00	Disclosure SEC source: 0000899243-19-017620 · doc4.xml · derivative · entry 2 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800 Underlying: Common Stock · 4,800 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 18, 2019 Filed Jun 20, 2019 16:04 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $56.30	$0.00	Disclosure SEC source: 0000899243-19-017620 · doc4.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-06-17 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 18, 2019, for 11 months and the remaining 1/12th on the earlier of (i) June 18, 2020 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
February 06, 2019 Filed Feb 8, 2019 17:23 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	GrantStock Option (right to buy) · Derivative	16,200	$0.00 Strike: $24.74	$0.00	Disclosure SEC source: 0001209191-19-008669 · doc4.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,200 Underlying: Common Stock · 16,200 shares Expires 2029-02-06 F1 · derivative.exercise_date: The option vests as to 100% of the shares upon the earlier of (i) the one-year anniversary of the grant date, and (ii) a Corporate Transaction of the Company as defined in the Company's 2016 Equity Incentive Plan; subject to the reporting person's continued service to the Company on the vesting date. Read SEC document
June 21, 2018 Filed Jun 25, 2018 20:05 UTC	Corvus Pharmaceuticals, Inc. CRVS · Entity 4839	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $12.50	$0.00	Disclosure SEC source: 0000899243-18-017915 · doc4.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-21 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document
June 20, 2018 Filed Jun 22, 2018 18:17 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $42.25	$0.00	Disclosure SEC source: 0000899243-18-017760 · doc4.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-19 F1 · derivative.exercise_date: The shares vest and become exercisable in 12 equal monthly installments, with the first installment on July 20, 2018, subject to the recipient's continued service on the Issuer's Board of Directors. This option is subject to accelerated vesting upon a change of control of the Issuer. Read SEC document
June 08, 2018 Filed Jun 8, 2018 17:22 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $38.65	$0.00	Disclosure SEC source: 0001209191-18-036739 · doc4.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-08 F1 · derivative.exercise_date: The option vests as to 100% of the shares upon the earliest of (i) the Company's 2019 annual meeting of stockholders, (ii) the one-year anniversary of the grant date, and (iii) a Corporate Transaction of the Company as defined in the Company's 2016 Equity Incentive Plan; subject to the reporting person's continued service to the Company on the vesting date. Read SEC document
October 08, 2017 Filed Oct 10, 2017 18:05 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	GrantStock Option (right to buy) · Derivative	9,000	$0.00 Strike: $26.01	$0.00	Disclosure SEC source: 0001209191-17-056527 · doc4.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2027-10-08 F1 · derivative.exercise_date: The option vests as to 100% of the shares upon the earliest of (i) the Company's 2018 annual meeting of stockholders, (ii) the one-year anniversary of the grant date, and (iii) a Corporate Transaction of the Company as defined in the Company's 2016 Equity Incentive Plan; subject to the reporting person's continued service to the Company on the vesting date. Read SEC document
June 20, 2017 Filed Jun 22, 2017 21:51 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $28.45	$0.00	Disclosure SEC source: 0000899243-17-017001 · doc4.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: The shares vest and become exercisable in 12 equal monthly installments, with the first installment on July 20, 2017, subject to the recipient's continued service on the Issuer's Board of Directors. This option is subject to accelerated vesting upon a change of control of the Issuer. Read SEC document
June 08, 2017 Filed Jun 9, 2017 20:05 UTC	Corvus Pharmaceuticals, Inc. CRVS · Entity 4839	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $9.70	$0.00	Disclosure SEC source: 0000899243-17-015929 · doc4.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-08 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2018 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.